Ajovy FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 7, 2025.
FDA Approved: Yes (First approved September 14, 2018)
Brand name: Ajovy
Generic name: fremanezumab-vfrm
Dosage form: Injection
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Migraine Prevention
Ajovy (fremanezumab) is a calcitonin gene-related peptide antagonist for the preventive treatment of migraine.
- Ajovy is a calcitonin gene-related peptide antagonist indicated for:
- the preventive treatment of migraine in adults, and
- the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
Development timeline for Ajovy
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.